Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPP4C | P60510 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.86 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.86 |
| ▸ | MAP1B | P46821 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fostriecin SCHEMBL62527 | 1.00 | PPP4C (1.00) | PPP4CMAPTTDP1MAP1BMEN1 | |
| Fostriecin SCHEMBL10030539 | 1.00 | PPP4C (1.00) | PPP4CMAPTTDP1MAP1BMEN1 | |
| Fostriecin SCHEMBL10738899 | 1.00 | PPP4C (1.00) | PPP4CMAPTTDP1MAP1BMEN1 | |
| Fostriecin SCHEMBL469219 | 1.00 | PPP4C (1.00) | PPP4CMAPTTDP1MAP1BMEN1 | |
| Fostriecin SCHEMBL5052 | 0.99 | PPP4C (0.98) | PPP4CMAPTTDP1MAP1BMEN1 | |
| Fostriecin SCHEMBL31052709 | 0.93 | MAPT (1.00) | PPP4CMAPTTDP1MAP1BMEN1 | |
| Fostriecin SCHEMBL29370092 | 0.93 | MAPT (1.00) | PPP4CMAPTTDP1MAP1BMEN1 | |
| Fostriecin SCHEMBL21408783 | 0.93 | MAPT (1.00) | PPP4CMAPTTDP1MAP1BMEN1 | |
| SCHEMBL444441 | 0.92 | PPP4C (0.86) | PPP4CMAPTTDP1MAP1BMEN1 | |
| SCHEMBL442237 | 0.92 | PPP4C (0.86) | PPP4CMAPTTDP1MAP1BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258420-A1 | Altered polypeptides, immunoconjugates thereof, and methods related thereto | BIOGEN IDEC MA INC. | 2009-10-15 | — | — | US | disclosed |
| US-20090258420-A1 | Altered polypeptides, immunoconjugates thereof, and methods related thereto | BIOGEN IDEC MA INC. | 2009-10-15 | — | — | US | disclosed |
| US-20070248988-A1 | Binding molecules and methods of use thereof | BIOGEN MA INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070248988-A1 | Binding molecules and methods of use thereof | BIOGEN MA INC. | 2007-10-25 | — | — | US | disclosed |
| US-4680416-A | Antibiotic CL-1565 complex derivatives | WARNER-LAMBERT COMPANY (US) | 1987-07-14 | — | — | US | disclosed |
| EP-0128651-A2 | Pyranones and related compounds and methods for their production and use | WARNER-LAMBERT COMPANY (US) | 1984-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258420-A1 | Altered polypeptides, immunoconjugates thereof, and methods related thereto | FCGR3B, FCGR2A, PTMS | PPP4C 1466/4885MAPT 4199/4885TDP1 3299/4885 |
| US-20070248988-A1 | Binding molecules and methods of use thereof | SHBG, CACYBP, CD2BP2 | PPP4C 1481/4885MAPT 3767/4885TDP1 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.